SCHEMBL3001244

SCHEMBL3001244

Cc1ccc(Cc2csc(N3CCN(S(=O)(=O)c4c(F)c(Br)cc(F)c4Br)CC3)n2)cc1C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
MAPK1 P28482 2/20 0.35
MAPT P10636 5/20 0.34
USP2 O75604 1/20 0.34
RECQL P46063 1/20 0.34
HSD17B10 Q99714 1/20 0.34
MEN1 O00255 4/20 0.34
KMT2A Q03164 4/20 0.34
LMNA P02545 3/20 0.34
HTR6 P50406 1/20 0.33
PKM P14618 2/20 0.33
CNR1 P21554 1/20 0.33
CNR2 P34972 1/20 0.33
POLB P06746 1/20 0.32
GAA P10253 1/20 0.32
TSHR P16473 1/20 0.32
HTT P42858 1/20 0.32
TP53 P04637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3017349 0.91 ALDH1A1 (0.37) ALDH1A1SMN1; SMN2L3MBTL1MAPK1MAPT
SCHEMBL3017973 0.90 ALDH1A1 (0.38) ALDH1A1SMN1; SMN2L3MBTL1MAPK1MAPT
SCHEMBL3021199 0.90 ALDH1A1 (0.37) ALDH1A1SMN1; SMN2L3MBTL1MAPK1MAPT
SCHEMBL3004059 0.89 MAPT (0.37) ALDH1A1SMN1; SMN2L3MBTL1MAPK1MAPT
SCHEMBL3019065 0.89 PROKR1 (0.38) ALDH1A1SMN1; SMN2L3MBTL1MAPK1MAPT
SCHEMBL3015133 0.89 ALDH1A1 (0.37) ALDH1A1SMN1; SMN2L3MBTL1MAPK1MAPT
SCHEMBL3006313 0.89 L3MBTL1 (0.37) ALDH1A1SMN1; SMN2L3MBTL1MAPK1MAPT
SCHEMBL3018686 0.89 SMN1; SMN2 (0.36) ALDH1A1SMN1; SMN2L3MBTL1MAPK1MAPT
SCHEMBL3652789 0.88 THRB (0.36) ALDH1A1SMN1; SMN2L3MBTL1MAPK1MAPT
SCHEMBL3012638 0.88 ALDH1A1 (0.36) ALDH1A1SMN1; SMN2L3MBTL1MAPK1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed
EP-2188272-A2 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV Remynd (BE) 2010-05-26 EP disclosed
WO-2009019295-A2 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV REMYND (BE) 2009-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ALDH1A1 3510/4885SMN1; SMN2 1/4885L3MBTL1 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.